×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:GNCA

Genocea Biosciences Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.01
$0.41
52-Week Range
$0.01
$2.27
Volume
83,513 shs
Average Volume
2.36 million shs
Market Capitalization
$933,807.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Genocea Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
18,767.9% Upside
$3.00 Price Target
Short Interest
Bearish
13.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$781,461 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.26) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.41 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Genocea Biosciences logo

About Genocea Biosciences (NASDAQ:GNCA) Stock

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

GNCA Stock News Headlines

GRPN, GNCA and LAB among mid-day movers
Genocea Biosciences to shut down
Genocea Closes Shop, Delists From NASDAQ
Genocea cuts two-thirds of staff, explores a sale
Genocea Biosciences to Host Investor Webinar
Genocea Biosciences: Q4 Earnings Snapshot
Genocea Provides Fourth Quarter 2021 Corporate Update
Genocea Biosciences Q4 2021 Earnings Preview
Genocea Biosciences Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNCA
Employees
74
Year Founded
N/A

Company Calendar

Last Earnings
10/27/2021
Today
7/06/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+18,767.9%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
2 Analysts

Profitability

Net Income
$-33,200,000.00
Pretax Margin
-1,946.15%

Debt

Sales & Book Value

Annual Sales
$1.64 million
Book Value
$0.47 per share

Miscellaneous

Free Float
57,788,000
Market Cap
$933,807.00
Optionable
Optionable
Beta
2.26














Genocea Biosciences Frequently Asked Questions

Should I buy or sell Genocea Biosciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Genocea Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNCA, but not buy additional shares or sell existing shares.
View analyst ratings for Genocea Biosciences
or view top-rated stocks.

What is Genocea Biosciences' stock price forecast for 2022?

2 equities research analysts have issued twelve-month price targets for Genocea Biosciences' stock. Their GNCA stock forecasts range from $3.00 to $3.00. On average, they anticipate Genocea Biosciences' share price to reach $3.00 in the next year. This suggests a possible upside of 18,767.9% from the stock's current price.
View analysts' price targets for Genocea Biosciences
or view top-rated stocks among Wall Street analysts.

How has Genocea Biosciences' stock price performed in 2022?

Genocea Biosciences' stock was trading at $1.16 on January 1st, 2022. Since then, GNCA stock has decreased by 98.6% and is now trading at $0.0159.
View the best growth stocks for 2022 here
.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a increase in short interest in May. As of May 31st, there was short interest totaling 3,590,000 shares, an increase of 118.9% from the May 15th total of 1,640,000 shares. Based on an average daily trading volume, of 8,010,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 13.6% of the shares of the stock are sold short.
View Genocea Biosciences' Short Interest
.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Genocea Biosciences
.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) released its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. During the same quarter last year, the business posted ($0.26) earnings per share.
View Genocea Biosciences' earnings history
.

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 53, Pay $837.42k)
  • Dr. Jessica Baker Flechtner Ph.D., Chief Scientific Officer (Age 50, Pay $585.18k)
  • Ms. Diantha Duvall CPA, M.B.A., CFO & Sec. (Age 50)
  • Ms. Jacquelyn L. Sumer, Chief Legal & Compliance Officer (Age 44)

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences CEO William Clark on Glassdoor.com. William Clark has an approval rating of 82% among Genocea Biosciences' employees.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.02.

How much money does Genocea Biosciences make?

Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $933,807.00 and generates $1.64 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Genocea Biosciences have?

Genocea Biosciences employs 74 workers across the globe.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for Genocea Biosciences is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192.

This page (NASDAQ:GNCA) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.